Subscribe
shutterstock_1246881214_piotr_swat
Piotr Swat / Shutterstock.com
11 February 2021Big PharmaAlex Baldwin

Celgene sues Dr Reddy’s over Pomalyst generic

Celgene has filed a lawsuit against Indian drugs manufacturer Dr Reddy’s Laboratories (DRL) to halt its plan to produce and market generic versions of Pomalyst (pomalidomide)—Celgene’s multiple myeloma treatment.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Celgene, Dr Reddy's abandon cancer drug patent dispute
1 February 2022   Bristol-Myers Squibb subsidiary, Celgene has settled its lawsuit against India-based drug maker Dr Reddy's over a generic version of the blockbuster cancer treatment, Pomalyst.
Big Pharma
Dr Reddy’s to receive $72m in Suboxone settlement
27 June 2022   India-based Dr Reddy’s has ended its litigation with Indivior and Aquestive Therapeutics over a generic version of opioid addiction treatment Suboxone sublingual film.
Americas
Lawsuit against Celgene, BMS and others moves forward
25 April 2023   New Jersey judge denies motion to stay antitrust action regarding blockbuster cancer drug | Defendants had argued litigation would be unnecessary and costly.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Celgene, Dr Reddy's abandon cancer drug patent dispute
1 February 2022   Bristol-Myers Squibb subsidiary, Celgene has settled its lawsuit against India-based drug maker Dr Reddy's over a generic version of the blockbuster cancer treatment, Pomalyst.
Big Pharma
Dr Reddy’s to receive $72m in Suboxone settlement
27 June 2022   India-based Dr Reddy’s has ended its litigation with Indivior and Aquestive Therapeutics over a generic version of opioid addiction treatment Suboxone sublingual film.
Americas
Lawsuit against Celgene, BMS and others moves forward
25 April 2023   New Jersey judge denies motion to stay antitrust action regarding blockbuster cancer drug | Defendants had argued litigation would be unnecessary and costly.

More on this story

Americas
Celgene, Dr Reddy's abandon cancer drug patent dispute
1 February 2022   Bristol-Myers Squibb subsidiary, Celgene has settled its lawsuit against India-based drug maker Dr Reddy's over a generic version of the blockbuster cancer treatment, Pomalyst.
Big Pharma
Dr Reddy’s to receive $72m in Suboxone settlement
27 June 2022   India-based Dr Reddy’s has ended its litigation with Indivior and Aquestive Therapeutics over a generic version of opioid addiction treatment Suboxone sublingual film.
Americas
Lawsuit against Celgene, BMS and others moves forward
25 April 2023   New Jersey judge denies motion to stay antitrust action regarding blockbuster cancer drug | Defendants had argued litigation would be unnecessary and costly.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?